Movement Alert｜ASYMCHEM Rises 5.09% in Regular Trading, CXO Sector Rally and Upcoming Interim Results Drive Rebound

Market Focus08-18

On August 18, ASYMCHEM rose 5.09% in regular trading, trading at HK$128.0/share, with turnover of HK$81.74 million.

On the news front, the pharmaceutical CXO sector rallied broadly, with ASYMCHEM benefiting from multiple catalysts. The company is scheduled to release its interim results for the period ending June 30 on August 24, with institutional views leaning bullish. WuXi AppTec previously reported mid-term results that significantly beat expectations, with first-half revenue of RMB 28.9 billion representing a 38.93% year-over-year increase, which triggered a sector-wide valuation recovery across CXO names.

Industry-level research notes indicate that the CXO sector has entered a new recovery cycle characterized by simultaneous domestic and overseas demand improvement, with ADC, peptide, and other novel modality pipelines remaining active. Global biopharma financing has continued to recover, and overseas orders at leading CXO companies have shown clear signs of rebound. The stock had previously pulled back over 5% on August 13 due to subsidiary loss disclosures and institutional selling, and the current move represents a recovery of that prior decline.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1135538834?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-18 11:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135538834","market":"us","top_or_hot":-1,"title":"Movement Alert｜ASYMCHEM Rises 5.09% in Regular Trading, CXO Sector Rally and Upcoming Interim Results Drive Rebound","media":"Market Focus","content":"<p><p>On August 18, ASYMCHEM rose 5.09% in regular trading, trading at HK$128.0/share, with turnover of HK$81.74 million.</p><p>On the news front, the pharmaceutical CXO sector rallied broadly, with ASYMCHEM benefiting from multiple catalysts. The company is scheduled to release its interim results for the period ending June 30 on August 24, with institutional views leaning bullish. WuXi AppTec previously reported mid-term results that significantly beat expectations, with first-half revenue of RMB 28.9 billion representing a 38.93% year-over-year increase, which triggered a sector-wide valuation recovery across CXO names.</p><p>Industry-level research notes indicate that the CXO sector has entered a new recovery cycle characterized by simultaneous domestic and overseas demand improvement, with ADC, peptide, and other novel modality pipelines remaining active. Global biopharma financing has continued to recover, and overseas orders at leading CXO companies have shown clear signs of rebound. The stock had previously pulled back over 5% on August 13 due to subsidiary loss disclosures and institutional selling, and the current move represents a recovery of that prior decline.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜ASYMCHEM Rises 5.09% in Regular Trading, CXO Sector Rally and Upcoming Interim Results Drive Rebound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜ASYMCHEM Rises 5.09% in Regular Trading, CXO Sector Rally and Upcoming Interim Results Drive Rebound\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-18 11:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 18, ASYMCHEM rose 5.09% in regular trading, trading at HK$128.0/share, with turnover of HK$81.74 million.</p><p>On the news front, the pharmaceutical CXO sector rallied broadly, with ASYMCHEM benefiting from multiple catalysts. The company is scheduled to release its interim results for the period ending June 30 on August 24, with institutional views leaning bullish. WuXi AppTec previously reported mid-term results that significantly beat expectations, with first-half revenue of RMB 28.9 billion representing a 38.93% year-over-year increase, which triggered a sector-wide valuation recovery across CXO names.</p><p>Industry-level research notes indicate that the CXO sector has entered a new recovery cycle characterized by simultaneous domestic and overseas demand improvement, with ADC, peptide, and other novel modality pipelines remaining active. Global biopharma financing has continued to recover, and overseas orders at leading CXO companies have shown clear signs of rebound. The stock had previously pulled back over 5% on August 13 due to subsidiary loss disclosures and institutional selling, and the current move represents a recovery of that prior decline.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06821","symbol_name":"凯莱英","start_time":0,"source_url":"","article_id":"1135538834","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135538834","pubTimestamp":1787025013,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 18, ASYMCHEM rose 5.09% in regular trading, trading at HK$128.0/share, with turnover of HK$81.74 million.On the news front, the pharmaceutical CXO sector rallied broadly, with ASYMCHEM...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06821":"凯莱英"},"translate_title":"走势警报|凯莱英常规交易中上涨 5.09%，CXO 板块反弹和即将公布的中期业绩推动反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06821":1},"content_text":"On August 18, ASYMCHEM rose 5.09% in regular trading, trading at HK$128.0/share, with turnover of HK$81.74 million.On the news front, the pharmaceutical CXO sector rallied broadly, with ASYMCHEM benefiting from multiple catalysts. The company is scheduled to release its interim results for the period ending June 30 on August 24, with institutional views leaning bullish. WuXi AppTec previously reported mid-term results that significantly beat expectations, with first-half revenue of RMB 28.9 billion representing a 38.93% year-over-year increase, which triggered a sector-wide valuation recovery across CXO names.Industry-level research notes indicate that the CXO sector has entered a new recovery cycle characterized by simultaneous domestic and overseas demand improvement, with ADC, peptide, and other novel modality pipelines remaining active. Global biopharma financing has continued to recover, and overseas orders at leading CXO companies have shown clear signs of rebound. The stock had previously pulled back over 5% on August 13 due to subsidiary loss disclosures and institutional selling, and the current move represents a recovery of that prior decline.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1135538834","isCrawlerRequest":true}